# Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis

> **NCT07120750** · — · NOT_YET_RECRUITING · sponsor: **Shenzhen Third People's Hospital** · enrollment: 332 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Chronic Hepatitis B

## Interventions

- **DRUG:** Intervention for Group 1
- **DRUG:** Intervention for Group 2

## Key facts

- **NCT ID:** NCT07120750
- **Lead sponsor:** Shenzhen Third People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07120750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07120750, "Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07120750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*